SBIR/STTR Funding

NIDA offers a broad range of funding opportunities that target all stages of biomedical product development (Ideation, Feasibility, and Product Development):

NIDA Entrepreneurial Development Funding Opportunities

To help researchers and entrepreneurs get their idea off the ground, NIDA offers several educational and training programs.

  • 2021 “100,00 to Start an SUD Startup” Challenge - A 3–6-month biomedical mentoring program that aims to test the premise of research ideas that can be fostered into biotech startups. Due date: November 16, 2021, Award Budget: $10,000
  • Entrepreneurship Training Program for Substance Use Researchers - An intensive 5-day in-person training course to teach diverse entrepreneurship and product development skills through case studies and dynamic presentations from leaders in the SUD field from the Yale Entrepreneurial Institute. Standard due dates: To be announced (Previous due date was June 30, 2021), Award Budget: Cost of travel, room, and board

NIDA participates in the National Institutes of Health SBIR and STTR Omnibus Funding Opportunity Announcements and Issues Notices for Targeted Solicitations

To help companies develop their innovative ideas, NIDA participated in the SBIR and STTR omnibus solicitation. The funding opportunity targets PI-initiated research (your own idea) that has the potential for technology commercialization and impact on public health.

  • 2021 NIH SBIR/STTR Omnibus Solicitation (Clinical trial required)
    • SBIR (PA-21-260)
    • STTR (PA-21-261
    • Standard due dates: January 5, April 5, and September 5, Award Budget: Ranges from $150,000 to $320,000 for Phase I, and $1 million to $2.5 million for Phase II
  • 2021 NIH SBIR/STTR Omnibus Solicitation (Clinical trial not allowed)
    • SBIR (PA-21-259)
    • STTR (PA-21-262
    • Standard due dates: January 5, April 5, and September 5, Award Budget: Ranges from $150,000 to $320,000 for Phase I, and $1 million to $2.5 million for Phase II

See additional information related to the Award Budget.

2021 NIDA SBIR/STTR Program Description Research Topics

Although NIDA considers a range of innovative technologies targeting substance use disorders, specific topic of interest for the NIDA SBIR/STTR programs include the following:

  • Biomarker development for substance use disorders
  • Substance use disorder drug discovery and development
  • Technologies for safe and controlled methadone dispensing for use at home
  • FDA-regulated medical devices for substance use disorders
  • Technological approaches to address stigma associated with substance use disorders
  • New technological approaches for the investigation, diagnosis, and certification of deaths related to drug overdose

NIDA-specific SBIR and STTR Targeted Funding Opportunities Announcements (FOA) (Feasibility and Product Development)

  • Advancing Validated Drug Targets for Substance Use Disorders (Clinical trial not allowed)
    • SBIR (RFA-DA-22-023)
    • STTR (RFA-DA-22-018)
    • Due date: February 18, 2022 Award Budget: Up to $320,000 for Phase I, and $2.5 million for Phase II
  • Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants Use Disorder - National Advisory Council on Drug Abuse (NACDA) approved concept, under FOA development; Due date: To be announced, Award Budget: To be announced

 Technical Assistance Programs (Feasibility)

  • Innovation Corps (I-CorpsTM) at NIH Program - An 8-week entrepreneurial training course for active Phase I SBIR and STTR awardees, Due date: To be announced, Award Budget: Up to $55,000

NIH Special Initiatives (Feasibility and Product Development)

  • Blueprint MedTech: Small Business Translator
    • SBIR (PAR-21-282) (Clinical trial optional)
    • Due date: October 21, 2021; February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 20, 2023; October 18, 2023; February 20, 2024; and June 20, 2024, Award Budget: Up to $320,000 for Phase I, and $2.5 million for Phase II
  • Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System
    • SBIR (PAR-20-111) (Clinical trial optional)
    • Due date: February 9, 2022; August 9, 2022; and February 9, 2023, Award Budget: Up to $320,000 for Phase I, and $2.5 million for Phase II
  • Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
    • SBIR and STTR  (PAR-21-345) (Administrative Supplement)
    • Due dates: not applicable, Award Budget: Direct costs for individual administrative supplements vary from less than $5,000 to more than $100,000 depending on the career level of the candidate
  • Administrative Supplement to Existing NIH Grants and Cooperative Agreements
    • SBIR and STTR (PA-20-272)
    • Due dates: not applicable, Award Budget: Limited to no more than the amount of the current parent award with total funding not to exceed NIDA’s hard caps
Archived Funding Opportunities
  • Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development 
  • Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction 
  • HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis
  • Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders
  • Novel Approaches to Decrease Stigma of Substance Use Disorders in Order to Facilitate Prevention, Treatment, and Supporting During Recovery
  • Rapid Assessment of Drug Abuse: Smart City Tools 
  • Digital Health Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD)
  • Blockchain Technology to Improve SUD Care 
  • Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders
  • Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders
  • Analytical Tools and Approaches for (Multidimensional) Scholarly Research Assessment and Decision Support in the Biomedical Enterprise 
  • Development of a Device to Objectively Measure Pain
  • Nasal Delivery of CNS Therapeutics
  • Wearable to Track Recovery and Relapse Factors for People w/ Addiction
  • Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research
  • Improved Technologies and Ligands for Non-invasive Brain Imaging
  • Laboratory and Diagnostic Tools to Advance Microbiome-Brain Research
  • Tools and Services for Designing Methodologically Rigorous Animal Studies
  • Tools for Monitoring and Manipulating Modified RNAs in the Nervous System
  • Abuse-Resistant and Abuse-Deterrent Formulations and Devices to Avoid the Abuse, Misuse and Diversion of Prescription Opioids by Patients (SBIR)
  • Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence